Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer |
| |
Authors: | Takayama Koichi Kawasaki Masayuki Ninomiya Kiyoshi Motohiro Akira Fujita Masaki Watanabe Kentaro Kajiki Akira Iwami Fumiyuki Miyazaki Naoki Izumi Miiru Hara Nobuyuki Nakanishi Yoichi;Fukuoka Lung Cancer Study Group Japan |
| |
Institution: | Research Institute for Diseases of the Chest, Kyushu University, Fukuoka,;Kitakyushu Municipal Medical Center, Kitakyushu,;National Fukuoka Higashi Hospital, Koga,;National Minami Fukuoka Hospital, Fukuoka,;Fourth Department of Internal Medicine, Fukuoka University, Fukuoka,;National Ohmuta Hospital, Ohmuta,;National Minami Kyushu Hospital, Kaiiki;and;Shin Nittetsu Yahata Memorial Hospital, Kitakyushu, Japan |
| |
Abstract: | Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2–43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients. |
| |
Keywords: | chemotherapy cisplatin low toxicity non-small cell lung cancer phase II study uracil-tegafur |
本文献已被 PubMed 等数据库收录! |
|